Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Syst Rev ; 13(1): 147, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38824585

ABSTRACT

INTRODUCTION: Personalised prevention aims to delay or avoid disease occurrence, progression, and recurrence of disease through the adoption of targeted interventions that consider the individual biological, including genetic data, environmental and behavioural characteristics, as well as the socio-cultural context. This protocol summarises the main features of a rapid scoping review to show the research landscape on biomarkers or a combination of biomarkers that may help to better identify subgroups of individuals with different risks of developing specific diseases in which specific preventive strategies could have an impact on clinical outcomes. This review is part of the "Personalised Prevention Roadmap for the future HEalThcare" (PROPHET) project, which seeks to highlight the gaps in current personalised preventive approaches, in order to develop a Strategic Research and Innovation Agenda for the European Union. OBJECTIVE: To systematically map and review the evidence of biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalised prevention in the general population, in clinical or public health settings. METHODS: Three rapid scoping reviews are being conducted in parallel (February-June 2023), based on a common framework with some adjustments to suit each specific condition (cancer, cardiovascular or neurodegenerative diseases). Medline and Embase will be searched to identify publications between 2020 and 2023. To shorten the time frames, 10% of the papers will undergo screening by two reviewers and only English-language papers will be considered. The following information will be extracted by two reviewers from all the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map. INCLUSION CRITERIA: Population: general adult populations or adults from specific pre-defined high-risk subgroups; concept: all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualised primary or secondary prevention of the diseases of interest; context: clinical or public health settings. SYSTEMATIC REVIEW REGISTRATION: https://doi.org/10.17605/OSF.IO/7JRWD (OSF registration DOI).


Subject(s)
Biomarkers , Precision Medicine , Humans , Precision Medicine/methods , Chronic Disease/prevention & control , Neoplasms/prevention & control , Cardiovascular Diseases/prevention & control , Neurodegenerative Diseases/prevention & control , Systematic Reviews as Topic
2.
BMC Cancer ; 19(1): 735, 2019 Jul 25.
Article in English | MEDLINE | ID: mdl-31345187

ABSTRACT

BACKGROUND: Many older patients don't receive appropriate oncological treatment. Our aim was to analyse whether there are age differences in the use of adjuvant chemotherapy and preoperative radiotherapy in patients with colorectal cancer. METHODS: A prospective cohort study was conducted in 22 hospitals including 1157 patients with stage III colon or stage II/III rectal cancer who underwent surgery. Primary outcomes were the use of adjuvant chemotherapy for stage III colon cancer and preoperative radiotherapy for stage II/III rectal cancer. Generalised estimating equations were used to adjust for education, living arrangements, area deprivation, comorbidity and clinical tumour characteristics. RESULTS: In colon cancer 92% of patients aged under 65 years, 77% of those aged 65 to 80 years and 27% of those aged over 80 years received adjuvant chemotherapy (χ2trends < 0.001). In rectal cancer preoperative radiotherapy was used in 68% of patients aged under 65 years, 60% of those aged 65 to 80 years, and 42% of those aged over 80 years (χ2trends < 0.001). Adjusting by comorbidity level, tumour characteristics and socioeconomic level, the odds ratio of use of chemotherapy compared with those under age 65, was 0.3 (0.1-0.6) and 0.04 (0.02-0.09) for those aged 65 to 80 and those aged over 80, respectively; similarly, the odds ratio of use of preoperative radiotherapy was 0.9 (0.6-1.4) and 0.5 (0.3-0.8) compared with those under 65 years of age. CONCLUSIONS: The probability of older patients with colorectal cancer receiving adjuvant chemotherapy and preoperative radiotherapy is lower than that of younger patients; many of them are not receiving the treatments recommended by clinical practice guidelines. Differences in comorbidity, tumour characteristics, curative resection, and socioeconomic factors do not explain this lower probability of treatment. Research is needed to identify the role of physical and cognitive functional status, doctors' attitudes, and preferences of patients and their relatives, in the use of adjuvant therapies.


Subject(s)
Colonic Neoplasms/therapy , Rectal Neoplasms/therapy , Age Factors , Aged , Aged, 80 and over , Chemotherapy, Adjuvant/standards , Chemotherapy, Adjuvant/statistics & numerical data , Colectomy , Colonic Neoplasms/epidemiology , Colonic Neoplasms/pathology , Comorbidity , Female , Humans , Male , Middle Aged , Neoadjuvant Therapy/methods , Neoadjuvant Therapy/standards , Neoadjuvant Therapy/statistics & numerical data , Neoplasm Staging , Practice Guidelines as Topic , Proctectomy , Prospective Studies , Rectal Neoplasms/epidemiology , Rectal Neoplasms/pathology , Socioeconomic Factors
3.
Br J Surg ; 105(13): 1853-1861, 2018 12.
Article in English | MEDLINE | ID: mdl-30102425

ABSTRACT

BACKGROUND: The aim of this study was to assess factors associated with outcomes after surgery for colorectal cancer and to design and internally validate a simple score for predicting perioperative mortality. METHODS: Patients undergoing surgery for primary invasive colorectal cancer in 22 centres in Spain between June 2010 and December 2012 were included. Clinical variables up to 30 days were collected prospectively. Multiple logistic regression techniques were applied and a risk score was developed. The Hosmer-Lemeshow test was applied and the area under the receiver operating characteristic (ROC) curve (AUC, with 95 per cent c.i.) was estimated. RESULTS: A total of 2749 patients with a median age of 68·5 (range 24-97) years were included; the male : female ratio was approximately 2 : 1. Stage III tumours were diagnosed in 32·6 per cent and stage IV in 9·5 per cent. Open surgery was used in 39·3 per cent, and 3·6 per cent of interventions were urgent. Complications were most commonly infectious or surgical, and 25·5 per cent of patients had a transfusion during the hospital stay. The 30-day postoperative mortality rate was 1·9 (95 per cent c.i. 1·4 to 2·4) per cent. Predictive factors independently associated with mortality were: age 80 years or above (odds ratio (OR) 2·76), chronic obstructive pulmonary disease (COPD) (OR 3·62) and palliative surgery (OR 10·46). According to the categorical risk score, a patient aged 80 years or more, with COPD, and who underwent palliative surgery would have a 23·5 per cent risk of death within 30 days of the intervention. CONCLUSION: Elderly patients with co-morbidity and palliative intention of surgery have an unacceptably high risk of death.


Subject(s)
Colorectal Neoplasms/mortality , Adult , Age Factors , Aged , Aged, 80 and over , Colorectal Neoplasms/complications , Colorectal Neoplasms/surgery , Comorbidity , Epidemiologic Methods , Female , Humans , Male , Middle Aged , Palliative Care/statistics & numerical data , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/mortality , Reoperation/statistics & numerical data , Young Adult
4.
Colorectal Dis ; 20(8): 676-687, 2018 08.
Article in English | MEDLINE | ID: mdl-29745479

ABSTRACT

AIM: Tools are needed to aid in the assessment of the prognosis of patients with rectal cancer regarding the risk of medium-term mortality. The aim of this study was to develop and validate clinical prediction rules for 1- and 2-year mortality in patients undergoing surgery for rectal cancer. METHOD: A prospective cohort study of patients diagnosed with rectal cancer who underwent surgery was carried out. The main outcomes were mortality at 1 and 2 years after surgery. Background, clinical parameters and diagnostic test findings were evaluated as possible predictors. Multivariable survival models were used in the statistical analyses. RESULTS: Predictors of 1-year mortality were being a current smoker [hazard ratio (HR) 4.98], having a Charlson index adjusted by age > 5 (HR 2.61), the presence of vascular, perineural or lymphatic invasion (HR 3.30), the presence of residual tumour at the operation (R-stage) (HR 8.64) and TNM stage (HR for TNM IV 5.10) [concordance index (C-index) 0.799 (95% CI: 0.71-0.89)]. Age greater than 80 years (HR 2.19), being a current smoker (HR 2.20), the pre-intervention haemoglobin level (HR 2.02), need for blood transfusion (HR 2.12), vascular, perineural or lymphatic invasion (HR 2.59), R-stage of the operation (HR 6.13) and TNM stage (HR for TNM IV 4.43) were predictors of 2-year mortality [C-index 0.779 (0.718-0.840)]. Adjuvant chemotherapy was an additional predictor at both outcome durations. CONCLUSION: These clinical parameters show good predictive values and are easy and quick-to-use tools to help in clinical decision making.


Subject(s)
Decision Support Techniques , Rectal Neoplasms/mortality , Rectal Neoplasms/surgery , Age Factors , Aged , Aged, 80 and over , Blood Transfusion , Chemotherapy, Adjuvant , Comorbidity , Hemoglobins/metabolism , Humans , Neoplasm Invasiveness , Neoplasm Staging , Neoplasm, Residual , Proportional Hazards Models , Prospective Studies , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Risk Factors , Smoking , Time Factors
5.
J Eur Acad Dermatol Venereol ; 31(12): 1991-1998, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28608530

ABSTRACT

Psoriasis is a chronic inflammatory disease that generally affects the skin, nails and joints. The burden of psoriatic disease in Latin America and the Caribbean (LAC) remains largely unknown. To estimate the burden of psoriasis in LAC. We conducted a systematic review following the MOOSE and PRISMA statements. We searched published studies in MEDLINE, EMBASE, LILACS and CENTRAL from 1st January 2000 to 5th August 2015. We included studies that reported incidence, prevalence, health resource use and health expenditures, treatment patterns, comparative effectiveness of different drugs, patients reported outcomes, adherence to treatment and patient preferences in LAC. Risk of bias was assessed evaluating selection of participants, control of cofounders, measurement of exposure and outcome and conflict of interest. Pairs of reviewers independently selected, extracted and assessed the bias risk of the studies. The systematic review was registered at PROSPERO (CRD42016038325). A total of 18 studies from 12 LAC countries were included. Most were observational studies, between which there was a large heterogeneity of outcomes. Population-based studies were not found and most data came from hospital registries. One study reported an incidence of psoriatic arthritis in 6.26 cases per 100 000 person-years. Another study found an incidence of psoriasis 1020 per 100 000 patient-year attending at a dermatology clinic. The prevalence reported in the Argentinean health service was 74 cases per 100 000. Further, psoriasis has been shown to have a substantial negative impact on quality of life. A number of studies also indicated that non-communicable disease burden increases with the presence and severity of psoriasis. With regard to treatment pattern, methotrexate was the dominant systemic therapy. In conclusion, there is an important lack of information from LAC concerning the burden of psoriasis. Further studies investigating the burden of psoriasis in representative LAC populations are needed.


Subject(s)
Psoriasis , Caribbean Region/epidemiology , Humans , Incidence , Latin America/epidemiology , Prevalence , Psoriasis/epidemiology , Psoriasis/therapy
6.
Int J Tuberc Lung Dis ; 18(12): 1415-20, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25517805

ABSTRACT

SETTING: Reported predictors of the adverse evolution of patients with chronic obstructive pulmonary disease exacerbations (eCOPD) are various and inconsistent in the bibliography. OBJECTIVE: To develop clinical prediction rules for short-term outcomes in eCOPD patients attending an emergency department (ED). DESIGN: Prospective cohort study of patients with an eCOPD. Short-term outcomes were admission to an intensive care unit (ICU), admission to an intermediate respiratory care unit (IRCU) and death in these groups. Multivariate logistic regression models were developed for each of the outcomes. RESULTS: Predictors of ICU or IRCU admission were use of long-term home oxygen therapy (LT-HOT) or non-invasive mechanical ventilation (NIMV), elevated PCO2 and decreased pH upon ED arrival (area under the curve [AUC] 0.87 in the derivation sample; 0.89 in the validation sample). Among those admitted to an ICU or IRCU, predictors of death were increased age, use at home of LT-HOT or NIMV, use of inspiratory accessory muscles upon ED arrival and altered Glasgow Coma Scale (<15 points) (AUC 0.78). CONCLUSIONS: Three clinical predictors available in the ED can be used to create a simple score to predict the need for intensive treatment among eCOPD patients. Such a score can be a tool for clinical practice.


Subject(s)
Decision Support Techniques , Emergency Service, Hospital , Pulmonary Disease, Chronic Obstructive/diagnosis , Age Factors , Aged , Aged, 80 and over , Area Under Curve , Disease Progression , Female , Glasgow Coma Scale , Hospital Mortality , Humans , Intensive Care Units , Logistic Models , Male , Multivariate Analysis , Odds Ratio , Oxygen Inhalation Therapy/adverse effects , Patient Admission , Predictive Value of Tests , Prognosis , Prospective Studies , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/physiopathology , Pulmonary Disease, Chronic Obstructive/therapy , ROC Curve , Respiration, Artificial/adverse effects , Risk Factors , Severity of Illness Index , Spain , Time Factors
7.
Med. prev ; 11(1): 9-14, ene.-mar. 2005.
Article in Es | IBECS | ID: ibc-040100

ABSTRACT

Objetivo: Valorar la evidencia científica acerca de la duración óptima de la profilaxis antimicrobiana quirúrgica. Material y Métodos: Revisión sistemática que incluye ensayos clínicos aleatorizados (ECAs) que comparan profilaxis antimicrobiana con monodosis prequirúrgica frente a profilaxis multidosis, publicados hasta Septiembre de 2004. Resultados: Se localizó una revisión sistemática publicada en 1998 que obtiene un OR de 1'04 con un Intervalo de Confianza (IC) al 95% [0'86-1'27] al comparar frecuencia de infección de localización quirúrgica en pacientes que reciben monodosis y multidosis. Tras esta revisión, se publicaron cuatro ECAs con los siguientes RR e IC al 95%: 2 [1'02-3'92], 0'51[0'10-2'65], 0'46[0'21-1'02] y 1'18[0'33-4'24]. Conclusiones: La administración de dosis adicionales de antimicrobiano posquirúrgicas no reduce la incidencia de infección de localización quirúrgica. No obstante, es preciso realizar nuevos ensayos clínicos para asentar esta evidencia en aquellas especialidades quirúrgicas con poca representación en los estudios realizados hasta ahora


Objective: To assess the scientific evidence about the optimum length for the antimicrobial prophylaxis in surgery. Methods: Systematic review including randomized clinical trials comparing single-dose preoperative prophylaxis with multiple-dose surgical prophylaxis, published until September 2004. Results: A systematic review published in 1998 was identified. The combined OR of surgical site infection for single versus multiple-dose prophylaxis was 1'04, 95% CI [0'86,1'27]. After this review another four trials were published with the following RR and CI 95%: 2 [1'02-3'92], 0'51 [0'10-2'65], 0'46 [0'21-l'02] and l'18[0'33-4'24]. Conclusions: Administration of postsurgery doses don't reduce the surgical site infection incidence. However, new trials are necessary to support this evidence in surgical disciplines with little participation in previous trials


Subject(s)
Humans , Antibiotic Prophylaxis/methods , Surgical Wound Infection/prevention & control , Anti-Bacterial Agents/administration & dosage , Surgical Wound Infection/drug therapy , Evidence-Based Medicine/methods , Clinical Trials as Topic/statistics & numerical data , Single Dose
SELECTION OF CITATIONS
SEARCH DETAIL
...